Skip to main content

Table 1 Clinical features of patients with circulating tumor cells

From: Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

 

No CTC (n = 39)

CTC (n = 34)

P value

Estimate (95% CI)

Age at primary diagnosis, years, mean (SD)

58.38 (11.85)

55.1 (11.04)

0.444

− 2.76 (− 8.49, 2.84)

Age at first CTC evaluation, years, mean (SD)

63.53 (11.69)

59.58 (10.7)

0.163

− 4.11 (− 9.27, 1.63)

Stage at diagnosis, n (%)

  

0.679

 I

4 (10.53%)

5 (14.71%)

  

 IA

1 (2.63%)

0 (0%)

  

 II

5 (13.16%)

4 (11.76%)

  

 IIA

1 (2.63%)

4 (11.76%)

  

 III

11 (28.95%)

7 (20.59%)

  

 IIIA

2 (5.26%)

0 (0%)

  

 IIIC

0 (0%)

2 (5.88%)

  

 IV

14 (36.84%)

11 (32.35%)

  

Lymphocyte node involvement, n (%)

  

0.881

 N0

11 (31.43%)

8 (25.81%)

  

 N1

11 (31.43%)

14 (45.16%)

  

 N2

6 (17.14%)

0 (0%)

  

 N3

6 (17.14%)

9 (29.03%)

  

Histologic subtype, n (%)

  

0.964

 Invasive lobular

6 (15.38%)

4 (11.76%)

  

 Invasive ductal

31 (79.49%)

29 (85.29%)

  

 Inflammatory invasive lobular

1 (2.56%)

1 (2.94%)

  

 Inflammatory

2 (5.13%)

2 (5.88%)

  

% of ER+ cells, mean (SD)

65.82 (42.48)

59.79 (40.93)

0.386

0 (− 10, 0)

% of PR+ cells, mean (SD)

38.97 (40.04)

26.35 (33.78)

0.171

− 4 (− 20, 0)

% of Ki-67+ cells, mean (SD)

27.08 (17.13)

31.59 (21.55)

0.514

5 (− 5, 10)

HER2+

7 (17.95%)

7 (22.58%)

0.766

1.33 (0.35–5.11)

Triple-negative

4 (10.81%)

3 (9.68%)

1.000

0.89 (0.12–5.73)

Tumor grade

  

0.985

 1

4 (10.53%)

4 (12.12%)

  

 2

17 (44.74%)

14 (42.42%)

  

 3

17 (44.74%)

15 (45.45%)

  

Bisphosphonates

9 (23.68%)

7 (20.59%)

0.784

0.84 (0.23–2.94)

Denosumab

16 (41.03%)

5 (14.71%)

0.019

0.25 (0.06–0.86)

Radiotherapy

22 (56.41%)

13 (38.24%)

0.160

0.48 (0.17–1.35)

Relapse

 Any

31 (79.49%)

25 (73.53%)

0.589

0.72 (0.21–2.45)

 Local

3 (7.69%)

4 (11.76%)

0.698

1.59 (0.25–11.72)

 Metastasis

26 (66.67%)

19 (55.88%)

0.470

0.64 (0.22–1.82)

Days between primary diagnosis and relapse, mean (SD)

1954.08 (2042.25)

1893.48 (1853.86)

0.966

− 9.37 (− 1000, 756)

Established metastatic disease at CTC evaluation

35 (89.74%)

30 (88.24%)

1.000

0.86 (0.15–5.04)

Number of metastatic sites, mean (SD)

2.09 (1.01)

1.9 (0.94)

0.473

0 (− 1, 0)

Metastasis site, n (%)

 Bone

27 (69.23%)

17 (51.52%)

0.150

0.45 (0.15–1.28)

 Liver

10 (25.64%)

12 (36.36%)

0.447

1.57 (0.51–4.9)

 Lymph node

9 (23.08%)

10 (30.3%)

0.599

1.38 (0.43–4.54)

 Pleural

7 (17.95%)

2 (6.06%)

0.162

0.29 (0.03–1.68)

 Peritoneal

3 (7.69%)

4 (12.12%)

0.698

1.59 (0.25–11.72)

 Lung

4 (10.26%)

4 (12.12%)

1.000

1.16 (0.2–6.83)

 Skin

3 (7.69%)

0 (0%)

0.243

0 (0–2.74)

 Brain

2 (5.13%)

2 (6.06%)

1.000

1.15 (0.08–16.76)

 Uterus

1 (2.56%)

1 (3.03%)

1.000

1.15 (0.01–92.67)

 Muscular

1 (2.56%)

2 (6.06%)

0.595

2.35 (0.12–143.61)

  1. Abbreviations: ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, PR Progesterone receptor
  2. The table shows clinical features of patients with and without circulating tumor cells (CTCs)